Anti-Human IL-6R (CD126) (Satralizumab) - 5 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

IL-6 is a pleiotropic cytokine that promotes B cell and T cell proliferation and differentiation andis also involved in the inflammatory response1. In the ‘classic’ signaling paradigm, IL-6 binds toits membrane bound receptor IL-6R to initiate intracellular signaling pathways2. Alternatively, in‘trans-signaling’, IL-6 binds to a soluble form of IL-6R. In both events, a complex set ofinteractions with membrane-bound or soluble β-receptor glycoprotein 130 (gp130) modulates thedownstream signaling pathways. Additionally, IL-6 plays an inflammatory role in autoimmunediseases3 and high IL-6 levels are a feature of cytokine storm and cytokine release syndromeduring COVID-19 infection1. IL-6 signaling can be inhibited by antibodies directed against IL-6R3.SA237 (Satralizumab) is a humanized monoclonal recycling antibody that was developed for thetreatment of neuromyelitis optica spectrum disorder, a rare autoimmune disease of the centralnervous system4. Satralizumab binds to both membrane and soluble IL-6R, thereby inhibitingIL-6 signaling as well as reducing inflammation and IL-6 mediated autoimmune T cell and B cellactivation. Ultimately, B cell differentiation into AQP4-IgG-secreting plasmablasts is prevented.Satralizumab circulation in the body is extended via a novel recycling technology that allows forpH dependent dissociation from IL-6R in the endosome after cellular uptake. Satralizumab isthen transported back to the plasma membrane via the recycling endosomal pathway andreleased into plasma for reuse. Satralizumab is produced in Chinese hamster ovary cells using recombinant DNA technology4.Satralizumab does not cross react with rodent IL-6R5.

≥ 5.0 mg/ml

IL-6R is mainly found on hepatocytes, some leukocytes, and epithelialcells. IL-6R also has a soluble form.